

M. SC. BIOINFORMATICS SEM.-III (2013 COURSE)
(CHOICE BASED CREDIT SYSTEMS) : WINTER - 2017

SUBJECT : CHEMINFORMATICS & DRUG DESIGN

Day : Saturday
Date : 28/10/2017

Time : 02.00 PM TO 05.00 PM
Max. Marks : 60

W-2017-1016

N.B :

- 1) **Q. 1 and Q. 5 are Compulsory.** Out of the remaining questions, attempt **any 2** from each sections.
- 2) Figures to the right indicate **Full** marks.
- 3) Answers to both the sections should be written in **Separate** answer books.

Section - I

- Q. 1** Define : **(10)**
- | | |
|---------------------------|----------------------------|
| a) Hosoya index | b) Adjacency Matrix |
| c) E-state | d) Pharmacophore |
| e) Molecular Shape | |
- Q. 2**
- | | |
|--|-------------|
| a) Explain SMARTS. | (02) |
| b) Describe electro-topological and refracto-topological descriptors. | (04) |
| c) Write short note on cheminformatics. | (04) |
- OR**
- c)** Define descriptors. Explain shape indices descriptors.
- Q. 3**
- | | |
|---|------------------------------|
| a) What is Vertex partition algorithm? | (02) |
| b) Explain followings: | (04) |
| 1) Tanimoto coefficient | 2) Euclidean distance |
| c) Explain Multiple Linear Regression (MLR). | (04) |
- OR**
- c)** How molecular databases are important in drug discovery research?
- Q. 4**
- | | |
|---|-------------|
| a) Define principal moment of inertia. | (02) |
| b) Write short note on ADMET. | (04) |
| c) How combinatorial library play important role in drug discovery research? | (04) |
- OR**
- c)** Discuss Lipinski's rule of five and define lead molecule.

Section - II

- Q. 5** Answer in brief: **(10)**
- | | |
|--|--|
| a) Name any four 3D descriptors. | |
| b) Define SMIRKS | |
| c) Write full form of SMILES. | |
| d) What is Tversky Index? | |
| e) Write a brief account on Autodock. | |
- Q. 6**
- | | |
|--|-------------|
| a) What is lead optimization? | (02) |
| b) Differentiate between ligand-based and structure-based drug design approaches with examples. | (04) |
- OR**
- b)** How can you identify and validate target site?
- c)** Discuss ab-initio drug design approach. **(04)**
- Q. 7**
- | | |
|--|-------------|
| a) Define structure-activity relationship (SAR). | (02) |
| b) Differentiate between 2D and 3D QSAR techniques with examples. | (04) |
| c) Explain stepwise derivation of 2D QSAR model. | (04) |
- OR**
- c)** Why validation of in-silico models are important?
- Q. 8**
- | | |
|---|-------------|
| a) Define virtual screening. | (02) |
| b) Differentiate between flexible and rigid docking. | (04) |
- OR**
- b)** Write short note on Scoring function.
- c)** Define pharmacophore. Explain steps of derivation of pharmacophore models. **(04)**

* * * * *